Q&A: Pierpaolo Ginefra on agility, and the choices that lead to - and on from-... The last of a 3-part series featuring members of our ECR community, with a glimpse into what drew them to life sciences, and where they're at in their careers.
The design of novel and optimized CAR T cells targeting both BCMA and TACI in the... Novel chimeric antigen receptors (CARs) with different configurations of the natural ligand APRIL for BCMA and TACI antigens delivered fast anti-tumor responses but did not protect from tumor recurrence, similar to CAR T cell therapies using antibody fragments for BCMA binding. The Arber Lab identifies potential mechanisms of resistance shared by different CAR T cell types targeting BCMA.
Fondation ISREC: appel à projets Tandem La Fondation ISREC lance un appel à projets soumis par des tandems, composés d’un.e clinicien.ne et d’un.e chercheur.euse ayant conçu conjointement un projet de recherche translationnelle qu’ils/elles co-dirigeront.